A Study of the Safety of CMA-676 in Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) in First Relapse

Inclusion Criteria

DISEASE CHARACTERISTICS: CD33 positive acute myeloid leukemia in first relapse At least 3
months of complete remission No history of a secondary leukemia evolving from a known
prior myelodysplastic syndrome or resulting from exposure to chemotherapy or toxins No
active CNS leukemia

PATIENT CHARACTERISTICS: Age: 60 and over Performance status: ECOG 0-2 Life expectancy:
Not specified Hematopoietic: WBC less than 30,000/mm3 at time of CMA-676 administration
Hepatic: Bilirubin no greater than 2.0 mg/dL Renal: Creatinine no greater than 3.0 mg/dL
Cardiovascular: No uncontrolled cardiac disease Pulmonary: No uncontrolled pulmonary
disease Other: No other active malignancy No uncontrolled, life-threatening infections
Able to obtain bone marrow aspirate HIV negative

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow and peripheral blood stem
cells transplantation No prior anti-CD33 antibody therapy Chemotherapy: Prior cytotoxic
chemotherapy for AML allowed No prior chemotherapy for AML in first relapse except
hydroxyurea At least 24 hours since prior hydroxyurea Recovered from prior antineoplastic
therapy (except alopecia) No concurrent cytotoxic chemotherapy Endocrine therapy: No
concurrent immunosuppressive therapy Radiotherapy: Not specified Surgery: Not specified
Other: At least 4 weeks since prior investigational agents No other concurrent
antileukemic therapy